Abstract
Distributional cost-effectiveness analysis (DCEA) is an extension of cost-effectiveness analysis that looks at the equity impact of adopting interventions, evaluating how health outcomes and costs are distributed in the population, and quantifying trade-offs between health maximisation and health equity. The National Institute of Health and Care Excellence (NICE) in the UK is exploring DCEA to support the development of its Technology Appraisals. The prevalence of diabetes and thus diabetic macular edema (DME), a complication of diabetes, is higher in more deprived areas. We aimed to conduct an aggregate DCEA from an English NHS perspective of treatments for DME recommended by NICE to capture the value of these treatments more comprehensively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
